Anavex Life Sciences Corp (AVXL)

[nidan7500]

Kevin...agree and [quoteAll biotech will be supercharged via improved bureaucratic efficiency at the FDA.
][/quote]


I believe the overall risks for investors will be lower in biotech due to the process changes and requirements of precision (prep) medicine. There may be a loss for those who do not even make the PII to III cut. Those trials which formerly might have made the cut to PIII may not w/new process requirements and acceptance criteria. If true we should benefit although it may take a while for this to play out.

At some point a retrospective review of historical big AD losers against new criteria would be interesting. This is going t put a lot of pressure on the FDA, as it should.